Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1

被引:64
|
作者
Cole, J. C. [1 ]
Lin, P. [1 ]
Rupnow, M. F. T. [2 ]
机构
[1] QualityMetric, Lincoln, RI 02865 USA
[2] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA
关键词
MSQ; migraine; prophylaxis; MID; MCID; HEALTH-STATUS MEASURES; ITEM RESPONSE THEORY; INTRAINDIVIDUAL CHANGES; RELIABILITY; IMPACT; RESPONSIVENESS; PREVENTION; TOPIRAMATE; VALIDITY; SCORE;
D O I
10.1111/j.1468-2982.2009.01852.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no published MID values exist for the MSQ v2.1 in any population. Analyses were performed on data from two pivotal clinical trials of topiramate for migraine prevention (n = 916), as well as from the QualityMetric National Headache Survey (n = 1016). Analyses included both distribution- and anchor-based MID techniques as well as group- and individual-level MID values. Group-level anchor-based MID values ranged from 3.2 [Role Restrictive domain (RR)] to 7.5 [Emotional Functioning domain (EF)], setting the minimum level of appropriate MID (which can also aid with power analysis). Individual-level distribution-based MID values resulted in highly similar estimates from two large databases: median MID of 8.5 for RR, 9.2 for Role Preventive (RP) and 12.0 for EF. Finally, individual-level anchor-based MID values ranged from 5.0 (RR and RP domains) to 10.6 (EF). For group-level purposes of calculating power for future studies, an MID of 3.2, 4.6 and 7.5 for RR, RP and EF is recommended. For within-group analyses for analysing clinical trial efficacy of each patient's change with responder analyses, 5 points is necessary for RR. For RP and EF, ranges are recommended: 5.0 to 7.9 for RP and 8.0 to 10.6 for EF. These latter two domains tend to have more error in the MID, and thus a sensitivity analysis with both ends of the range should be used to confirm significant differences in responder analyses.
引用
收藏
页码:1180 / 1187
页数:8
相关论文
共 50 条
  • [41] Network meta-analysis of atogepant vs. CGRP mAbs on migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine
    Ailani, J.
    Dupont-Benjamin, L.
    Tassorelli, C.
    Sacco, S.
    Nahas, S. J.
    Lalla, A.
    Ubamadu, I.
    Pietri, G.
    Gandhi, P.
    Singh, R. B. Halker
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [42] Improvement in migraine-specific quality of life in a clinical trial of rizatriptan
    Santanello, NC
    Polis, AB
    Hartmaier, SL
    Kramer, MS
    Block, GA
    Silberstein, SD
    CEPHALALGIA, 1997, 17 (08) : 867 - 872
  • [43] Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life Questionnaire
    Askew, Robert L.
    Xing, Yan
    Palmer, J. Lynn
    Cella, David
    Moye, Lemuel A.
    Cormier, Janice N.
    VALUE IN HEALTH, 2009, 12 (08) : 1144 - 1150
  • [44] Effect of fremanezumab on migraine-specific quality of life in Korean patients with chronic and episodic migraine
    Kim, Byung-Kun
    Seo, Dayoung
    Woo, Yunna
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [45] Validation of a migraine-specific questionnaire for use in family studies
    Kallela, M
    Wessman, M
    Färkkilä, M
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (01) : 61 - 66
  • [46] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine
    Lipton, R. B.
    Gandhi, S. K.
    Fitzgerald, T.
    Yeung, P. P.
    Cohen, J. M.
    Ma, Y.
    Aycardi, E.
    HEADACHE, 2018, 58 : 129 - 129
  • [47] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine
    Lipton, Richard B.
    Gandhi, Sanjay K.
    Fitzgerald, Timothy
    Yeung, Paul P.
    Cohen, Joshua M.
    Ma, Yuju
    Aycardi, Ernesto
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [48] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine
    Lipton, Richard B.
    Gandhi, Sanjay K.
    Fitzgerald, Timothy
    Yeung, Paul P.
    Cohen, Joshua M.
    Ma, Yuju
    Aycardi, Ernesto
    NEUROLOGY, 2018, 90
  • [49] MIGRAINE-SPECIFIC QUALITY-OF-LIFE - A COMPARISON OF US AND CANADIAN RESULTS
    BABIAK, LM
    MILLER, DW
    MACMILLAN, JH
    SPRANG, G
    QUALITY OF LIFE RESEARCH, 1994, 3 (01) : 58 - 58
  • [50] Further development and testing of the migraine-specific quality of life (MSQOL) measure
    Patrick, DL
    Hurst, BC
    Hughes, J
    HEADACHE, 2000, 40 (07): : 550 - 560